The current clinical trial process in the United States is on shaky ground. In this era of personalized medicine, as diseases are increasingly defined by specific genetic and biologic markers and treatments are tailored accordingly, patient populations for new therapies grow smaller and smaller. Coupled with skyrocketing costs and expanding regulatory requirements, the completion of trials that are essential in bringing new and effective therapies to patients is no easy task.
On March 3 in the New England Journal of Medicine, a group of researchers from around the world propose a new model to revitalize the research engine in this country -- collaborative clinical trials. They believe collaborative trials -- in which different companies team up and share the costs to test new therapies or devices -- will ensure safe and effective treatments become available more quickly and at a lower cost than they do today.
步入"集体临床试验"时代---http://www.sciencedaily.com/releases/2011/03/110302171307.htm
Pharmacies sell your prescription records to data mining companies, who aggregate the information and sell it to drug companies for billions of dollars per year. Drug companies use it to sell drugs. Lots of drugs. Vermont physicians were appalled, and the state passed a law in 2007 extending privacy protections to prescription records that identified the physician.
佛蒙特州数据挖掘案 (Sorrell v. IMS Health)--http://feedproxy.google.com/~r/TheIncidentalEconomist/~3/HXhGtCvXEPM/
